IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1751 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2184    
    Printed71    
    Emailed1    
    PDF Downloaded377    
    Comments [Add]    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2014  |  Volume : 80  |  Issue : 4  |  Page : 296--299

Factors affecting the duration of phase I of dexamethasone - cyclophosphamide pulse therapy


Department of Dermatology, Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai Central, Mumbai, India

Correspondence Address:
Chitra S Nayak
Topiwala National Medical College and BYL Nair Charitable Hospital, Dr. AL Nair Road, Mumbai Central, Mumbai - 400 008
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.136831

Rights and Permissions

Background: The introduction of dexamethasone-cyclophosphamide pulse (DCP) therapy for the pemphigus group of disorders by Pasricha has revolutionized the therapy for pemphigus. There are very few studies regarding factors affecting duration of phase I of the DCP. Aims: Our purpose was to study the relationship between various factors and duration of the phase I. Methods: A retrospective study of 98 patients of pemphigus on Dexamethasone Pulse therapy was conducted. Patients were classified according to duration of Phase 1 as those with phase I less than 6 months and those more than 6 months and analyzed for variable factors affecting duration of phase I. Results: Disease severity in pemphigus significantly prolonged the duration of phase I of DCP. Longer duration was also observed in patients on concurrent oral steroid therapy (both statistically significant). Conclusion: The findings from our study help us to address patient expectations and apprehensions regarding duration of therapy. A detailed understanding of the various patient and disease related factors responsible for affecting Phase I duration will help in better management of the patient, and the disease.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow